Posted by Michael Wonder on 15 Jun 2022
Another week, another terminated NICE appraisal
15 June 2022 - It should not come as a surprise that it is for a cancer medicine.
NICE is unable to make a recommendation on the use of enfortumab vedotin for patients with previously treated locally advanced or metastatic urothelial cancer because Astellas did not provide an evidence submission.
